Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)
Shares of GlaxoSmithKline plc (ADR) (NYSE: GSK) are up 3% after Human Genome Sciences (NASDAQ: HGSI) received approval from the FDA for its lupus drug Benlysta. Benlysta is the first lupus drug approved in the country in 56 years. Many are now speculating that the Benlysta approval may finally allow GlaxoSmithKline to purchase Human Genome Sciences.
Other drug companies that have lupus drugs related to their pipeline are La Jolla Pharmaceutical (NASDAQ: LJPC), Anthera Pharmaceuticals (NASDAQ: ANTH) Cephalon (NASDAQ: CEPH), AND Eli Lilly and Co. (NYSE: LLY).
At last check, shares of GlaxoSmithKline were up $1.14 to $39.72, a gain of 2.95%.
A relatively comprehensive article of publicly-traded companies that compete in the Lupus drug space can be found here. Traders will be watching these companies closely when Human Genome Sciences reopens for trading after the full dissemination of Benlysta FDA approval news.
